Evidence map›Paper›PMID 32039393›Full record

ArticleJHEP reports : innovation in hepatology2019

Paul F Lebeau, Jae Hyun Byun, Khrystyna Platko, Ali A Al-Hashimi, Šárka Lhoták, Melissa E MacDonald, Aurora Mejia-Benitez, Annik Prat, Suleiman A Igdoura, Bernardo Trigatti and 3 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 80 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. MOR23 deficiency exacerbates hepatic steatosis in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Paul F LebeauDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Jae Hyun ByunDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Khrystyna PlatkoDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Ali A Al-HashimiDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Šárka LhotákDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Melissa E MacDonaldDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Aurora Mejia-BenitezDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
Annik PratLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, affiliated to the University of Montreal, Montreal, Quebec H2W 1R7, Canada.
Suleiman A IgdouraDepartment of Biology and Pathology, McMaster University, Hamilton, Ontario, L8S 4K1, Canada.
Bernardo TrigattiThrombosis and Atherosclerosis Research Institute (TaARI), Hamilton Health Sciences and McMaster University, Hamilton, Ontario L8L 2X2, Canada.
Kenneth N Macleanthe Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA, 80045.
Nabil G SeidahLaboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, affiliated to the University of Montreal, Montreal, Quebec H2W 1R7, Canada.
Richard C AustinDepartment of Medicine, Division of Nephrology, McMaster University, St. Joseph's Healthcare Hamilton, Ontario L8N 4A6, Canada.
St. Joseph’s Healthcare Hamilton · CAMcMaster University · CAMontreal Clinical Research Institute · CAThrombosis and Atherosclerosis Research Institute · CAUniversité de Montréal · CAUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fatty acid translocase, also known as CD36, is a well-established scavenger receptor for fatty acid (FA) uptake and is abundantly expressed in many metabolically active tissues. In the liver, CD36 is known to contribute to the progression of non-alcoholic fatty liver disease and to the more severe non-alcoholic steatohepatitis, by promoting triglyceride accumulation and subsequent lipid-induced endoplasmic reticulum (ER) stress. Given the recent discovery that the hepatocyte-secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) blocks CD36 expression, we sought to investigate the role of PCSK9 in liver fat accumulation and injury in response to saturated FAs and in a mouse model of diet-induced hepatic steatosis.

methodsIn this study, we investigated the role of PCSK9 on the uptake and accumulation of FAs, as well as FA-induced toxicity, in a variety of cultured hepatocytes. Diet-induced hepatic steatosis and liver injury were also assessed in

resultsOur results indicate that PCSK9 deficiency in cultured hepatocytes increased the uptake and accumulation of saturated and unsaturated FAs. In the presence of saturated FAs, PCSK9 also protected cultured hepatocytes from ER stress and cytotoxicity. In line with these findings, a metabolic challenge using a high-fat diet caused severe hepatic steatosis, ER stress inflammation and fibrosis in the livers of

conclusionsCollectively, our findings demonstrate that PCSK9 regulates hepatic triglyceride content in a manner dependent on CD36. In the presence of excess dietary fats, PCSK9 can also protect against hepatic steatosis and liver injury. LAY SUMMARY: The proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein known to reduce the abundance of receptors on the surface of liver cells charged with the task of lipid uptake from the circulation. Although PCSK9 deficiency is known to cause lipid accumulation in mice and in cultured cells, the toxicological implications of this observation have not yet been reported. In this study, we demonstrate that PCSK9 can protect against cytotoxicity in cultured liver cells treated with a saturated fatty acid and we also show that

Indexed as

Cardiometabolic diseaseCD36CVDER stressHFDLiver diseaseNAFLD

Identifiers

PMID32039393
PMCPMC7005770
OpenAlexW2988581613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.